Sfoglia per Autore  

Opzioni
Mostrati risultati da 21 a 40 di 347
Titolo Tipologia Data di pubblicazione Autori File
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort 01 - Articolo su rivista 2023 Cairoli R.Gambacorti-Passerini C. +
Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma 01 - Articolo su rivista 2023 Mastini C.D’Aliberti D.Mologni L.Piazza R.Gambacorti Passerini C. +
Evaluating the performance of large language models in haematopoietic stem cell transplantation decision-making 01 - Articolo su rivista 2023 Civettini, IvanZappaterra, AriannaGranelli, Bianca MariaRindone, GiovanniAroldi, AndreaBonfanti, StefanoColombo, FedericaFedele, MarilenaPerfetti, PaolaTerruzzi, ElisabettaGambacorti-Passerini, CarloRamazzotti, DanieleCavalca, Fabrizio +
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study 01 - Articolo su rivista 2023 Gambacorti-Passerini C. +
Safety and Effectiveness of Intensive Treatments Administered Outside the Intensive Care Unit to Hematological Critically Ill Patients: An Intensive Care without Walls Trial 01 - Articolo su rivista 2023 Verga L.Gambacorti-Passerini C.Foti G. +
Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia 01 - Articolo su rivista 2023 Inzoli E.Civettini I.Montelisciani L.Antolini L.Gambacorti-Passerini C.Elli E. M. +
MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia 01 - Articolo su rivista 2023 Gambacorti-Passerini C. +
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study 01 - Articolo su rivista 2023 Piazza R.Guglielmana V.Colombo F.Antolini L.Gambacorti-Passerini C. +
Author Correction: Analyses of non-coding somatic drivers in 2,658 cancer whole genomes (Nature, (2020), 578, 7793, (102-111), 10.1038/s41586-020-1965-x) 99 - Altro 2023 Gambacorti-Passerini C. +
Author Correction: The repertoire of mutational signatures in human cancer (Nature, (2020), 578, 7793, (94-101), 10.1038/s41586-020-1943-3) 99 - Altro 2023 Gambacorti-Passerini C. +
Author Correction: Pan-cancer analysis of whole genomes (Nature, (2020), 578, 7793, (82-93), 10.1038/s41586-020-1969-6) 99 - Altro 2023 Gambacorti-Passerini C. +
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study 01 - Articolo su rivista 2022 Gambacorti Passerini C. +
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706) 01 - Articolo su rivista 2022 Bossi, ElisaAroldi, AndreaBorin, Lorenza MariaVerga, LuisaFontana, DilettaCocito, FedericaManghisi, BeatriceRindone, GiovanniCavalca, FabrizioRipamonti, AlessiaAntolini, LauraPiazza, Rocco GiovanniGambacorti-Passerini, Carlo +
Characterization of the transcriptional landscape of atypical Chronic Myeloid Leukemia at single-cell resolution 02 - Intervento a convegno 2022 Fontana, DCrippa, VBassi, GD'Aliberti, DMauri, MSpinelli, SMastini, CBombelli, SCivettini, IGuglielmana, VRamazzotti, DMologni, LPiazza, RGambacorti Passerini, C +
Clinical and Molecular features of the patients with Idiopathic Erythrocytosis 02 - Intervento a convegno 2022 Elli, EMauri, MD’Aliberti, DCrespiatico, IFontana, DRedaelli, SPelucchi, SManghisi, BCavalca, FRipamonti, ARamazzotti, DPiperno, AGambacorti Passerini, CPiazza, R +
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial 01 - Articolo su rivista 2022 Gambacorti-Passerini, Carlo +
Identification of non-ATP-competitive α-carboline inhibitors of the anaplastic lymphoma kinase 01 - Articolo su rivista 2022 Mologni, LucaCeccon, MonicaViltadi, MichelaVece, VitoGambacorti-Passerini, Carlo +
Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns (Nature Communications, (2020), 11, 1, (728), 10.1038/s41467-019-13825-8) 99 - Altro 2022 Gambacorti-Passerini C. +
Author Correction: Divergent mutational processes distinguish hypoxic and normoxic tumours (Nature Communications, (2020), 11, 1, (737), 10.1038/s41467-019-14052-x) 99 - Altro 2022 Gambacorti-Passerini C. +
Author Correction: Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig (Nature Communications, (2020), 11, 1, (731), 10.1038/s41467-020-14352-7) 99 - Altro 2022 Gambacorti-Passerini C. +
Mostrati risultati da 21 a 40 di 347
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile